AI deciphers city designs that could cut heart disease rates

Patients with unfavorable cancer of unknown primary (CUP) lived significantly longer without disease progression when they received molecularly guided therapy (MGT) instead of chemotherapy, according

Pfiz­er an­nounced Fri­day morn­ing that the FDA ap­proved its gene ther­a­py for the rare ge­net­ic bleed­ing dis­or­der he­mo­phil­ia B. The one-time treat­ment, known gener­i­cal­ly as